Compare QTWO & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QTWO | XENE |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.2B |
| IPO Year | 2014 | 2014 |
| Metric | QTWO | XENE |
|---|---|---|
| Price | $49.01 | $56.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $84.45 | $67.17 |
| AVG Volume (30 Days) | 585.9K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.00 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $193,978,000.00 | $311,000.00 |
| Revenue This Year | $12.48 | N/A |
| Revenue Next Year | $10.18 | $2,436.26 |
| P/E Ratio | $59.68 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $44.65 | $26.74 |
| 52 Week High | $95.10 | $62.91 |
| Indicator | QTWO | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 48.12 | 62.01 |
| Support Level | $45.41 | $39.93 |
| Resistance Level | $52.96 | $62.91 |
| Average True Range (ATR) | 1.91 | 1.87 |
| MACD | 0.43 | -0.23 |
| Stochastic Oscillator | 64.33 | 63.35 |
Q2 Holdings Inc provides digital solutions to financial institutions, financial technology companies, and alternative finance companies, seeking to incorporate banking into their customer engagement and servicing strategies. The company helps its clients with supervisory, consumer protection, privacy, third-party risk management requirements, and cyber threats and fraud, among other applications, by offering a portfolio of digital solutions, which comprises its digital banking offerings, digital lending and relationship pricing solutions, risk and fraud solutions, as well as Q2 Innovation Studio and Helix. Q2 derives the majority of its revenue from subscription fees for the use of its hosted solutions.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.